CA2458394C - Lipophilic drug compositions - Google Patents

Lipophilic drug compositions Download PDF

Info

Publication number
CA2458394C
CA2458394C CA2458394A CA2458394A CA2458394C CA 2458394 C CA2458394 C CA 2458394C CA 2458394 A CA2458394 A CA 2458394A CA 2458394 A CA2458394 A CA 2458394A CA 2458394 C CA2458394 C CA 2458394C
Authority
CA
Canada
Prior art keywords
lipid
molecule
drug
biologically active
encapsulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2458394A
Other languages
English (en)
French (fr)
Other versions
CA2458394A1 (en
Inventor
Michael T. Sung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2458394A1 publication Critical patent/CA2458394A1/en
Application granted granted Critical
Publication of CA2458394C publication Critical patent/CA2458394C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2458394A 2001-08-23 2002-08-21 Lipophilic drug compositions Expired - Fee Related CA2458394C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31409201P 2001-08-23 2001-08-23
US60/314,092 2001-08-23
US10/134,329 US7125568B2 (en) 2001-08-23 2002-04-29 Lipophilic drug compositions
US10/134,329 2002-04-29
PCT/US2002/026571 WO2003018064A2 (en) 2001-08-23 2002-08-21 Lipophilic drug compositions

Publications (2)

Publication Number Publication Date
CA2458394A1 CA2458394A1 (en) 2003-03-06
CA2458394C true CA2458394C (en) 2013-04-23

Family

ID=26832219

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2458394A Expired - Fee Related CA2458394C (en) 2001-08-23 2002-08-21 Lipophilic drug compositions

Country Status (6)

Country Link
US (2) US7125568B2 (OSRAM)
EP (1) EP1420828B1 (OSRAM)
CA (1) CA2458394C (OSRAM)
ES (1) ES2395408T3 (OSRAM)
TW (1) TWI302459B (OSRAM)
WO (1) WO2003018064A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680087A1 (en) * 2003-10-31 2006-07-19 Teva Pharmaceutical Industries Limited Nanoparticles for drug delivery
CA2604640A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
AU2007204963B2 (en) * 2006-01-09 2012-09-27 Romark Laboratories, L.C. Viral hepatitis treatment
US20100119529A1 (en) * 2006-05-12 2010-05-13 Furgeson Darin Y Elastin-like polymer delivery vehicles
WO2008101173A2 (en) * 2007-02-16 2008-08-21 Cornell University Biodegradable compositions and materials
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US7790401B2 (en) * 2007-08-06 2010-09-07 Siemens Healthcare Diagnostics Methods for detection of immunosuppressant drugs
TW200936180A (en) * 2007-11-27 2009-09-01 Intervet Int Bv Carrier particle for a microorganism or subunit thereof, pharmaceutical composition comprising such particles, method for preparation of this composition and its use in the treatment of animals
GB0724550D0 (en) * 2007-12-18 2008-01-30 Univ Hull Formulations
GB0812513D0 (en) * 2008-07-09 2008-08-13 Univ Hull Delivery vehicle
WO2011044136A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid acipimox derivatives and their uses
WO2012054334A1 (en) * 2010-10-20 2012-04-26 Galderma S.A. Method of treating herpes virus infection using macrocyclic lactone compound
CA2929538A1 (en) * 2013-11-05 2015-05-14 Ultragenyx Pharmaceutical Inc. Creatine analogs and the use thereof
WO2017223447A1 (en) * 2016-06-23 2017-12-28 The Regents Of The University Of Michigan 12(s)-hydroxyeicosatrienoic acid compounds and their use as therapeutic agents
AU2018375199B2 (en) 2017-12-01 2023-03-30 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US3931213A (en) 1974-12-18 1976-01-06 Interx Research Corporation 3-Chloro-2-oxazolidinones
DE2655369A1 (de) 1976-12-03 1978-06-08 Schering Ag 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung
US4315018A (en) 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
ATE78158T1 (de) 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US5340587A (en) 1985-05-22 1994-08-23 Liposome Technology, Inc. Liposome/bronchodilator method & System
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
CA1317594C (en) 1987-10-21 1993-05-11 Chung-Ho Park Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
DE68916439T2 (de) 1988-10-05 1994-10-20 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5043165A (en) 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
DE69125750D1 (de) 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
US6147204A (en) 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6060080A (en) 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
DK0580817T3 (da) 1991-04-19 1996-08-05 Nexstar Pharmaceuticals Inc Farmaceutisk præparat og fremgangsmåde til fremstilling deraf
KR100257418B1 (ko) 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
PL174222B1 (pl) 1993-01-27 1998-06-30 Inst Farmaceutyczny Środek farmaceutyczny działający na ośrodkowy układ nerwowy
US5512671A (en) 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5668286A (en) 1994-03-15 1997-09-16 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions containing them
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5599831A (en) 1994-05-27 1997-02-04 Poretz; Ronald D. Method of preparation of pharmaceutical compositions
DE69535758D1 (de) 1994-08-29 2008-07-03 Univ Wake Forest Lipid-analoge zur behandlung von viralen infektionen
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
CA2210500A1 (en) 1995-01-16 1996-07-25 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound - fatty acid conjugates
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
HUP9901979A3 (en) 1995-09-01 2000-03-28 Upjohn Co Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings and pharmaceutical compositions containing the same
ES2192221T3 (es) 1995-10-30 2003-10-01 Oleoyl Estrone Developments S Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso.
ZA969622B (en) 1995-12-13 1998-05-15 Upjohn Co Oxazolidinone antibacterial agents having a six-membered heteroaromatic ring.
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6153119A (en) 1997-05-09 2000-11-28 Sung; Michael Method and product for reducing tar and nicotine in cigarettes
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
SK20332000A3 (sk) 1998-07-14 2001-05-10 Pharmacia & Upjohn Použitie oxazolidinónov
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
GB9930026D0 (en) 1999-12-21 2000-02-09 Univ Sheffield Novel compounds of unsaturated fatty acids
US6288238B1 (en) 2000-09-19 2001-09-11 Board Of Trustees Operating Michigan State University Process for the preparation of 5-hydroxymethyl 2-oxazolidinone and novel intermediate
WO2002076404A2 (en) 2001-03-23 2002-10-03 Protarga, Inc. Fatty alcohol drug conjugates

Also Published As

Publication number Publication date
EP1420828B1 (en) 2012-09-26
CA2458394A1 (en) 2003-03-06
US20030108596A1 (en) 2003-06-12
WO2003018064A2 (en) 2003-03-06
WO2003018064A3 (en) 2003-09-25
US7390506B2 (en) 2008-06-24
EP1420828A2 (en) 2004-05-26
TWI302459B (OSRAM) 2008-11-01
US20060147525A1 (en) 2006-07-06
ES2395408T3 (es) 2013-02-12
US7125568B2 (en) 2006-10-24

Similar Documents

Publication Publication Date Title
CA2458394C (en) Lipophilic drug compositions
US20060078618A1 (en) Lipid particles and suspensions and uses thereof
US8950583B2 (en) Method to remove heavy metals from a mammal
NL8002097A (nl) Parenteraal toedienbare stabiele geneesmiddel- oplossingen.
US20130108605A1 (en) Method of ameliorating oxidative stress and supplementing the diet
JP2010503691A (ja) ７‐エチル‐１０‐ヒドロキシカンプトセシンのマルチアームポリマー複合体を用いた非ホジキンリンパ腫の治療方法
US8575218B2 (en) Thiol-containing compounds for the removal of elements from tissues and formulations therefor
DE102009043342A1 (de) Stoffe für selbstorganisierte Träger zur kontrollierten Freisetzung eines Wirkstoffs
JPS61246134A (ja) 腸管吸収化合物および複合体
TW201438713A (zh) 治療帕金森疾病的新穎高穿透性藥物和醫藥組合物
HUP0300133A2 (en) Amphiphilic polymers and polypeptide conjugates comprising same
CA2446622C (en) Isostearic acid salts as permeation enhancers
EP1349578B1 (fr) Association medicamenteuse d'une biguanine (metformine) et d'arginine
US8304565B2 (en) PEG-lipid conjugates for liposomes and drug delivery
JP2007504256A (ja) 生物活性剤の送達のための組成物及び方法
ES2431316T3 (es) Sistema de nanotransporte con arquitectura dendrítica
JP3804452B2 (ja) 肝炎治療剤
JP6039157B2 (ja) 膀胱癌の治療のための組成物及び治療法
CA1259750A (fr) Derives lipophiles de muramylpeptides ayant des proprietes d'activation des macrophages, compositions les contenant et procede pour les obtenir
AU2002329796B2 (en) Lipophilic drug compositions
JP5009621B2 (ja) チオール開裂し得るマイトマイシンコンジュゲート
AU2002329796A1 (en) Lipophilic drug compositions
CN108699060A (zh) 结合有脂肪酸的恩替卡韦衍生化合物及其药学用途
WO2011004393A4 (en) Para amino benzoic acid based nanotubes
WO2009007827A2 (en) Novel diclofenac esters and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150821